All News

A phase 1/2 trial evaluating seclidemstat plus Vidaza resumed patient enrollment for those with certain blood cancers and another phase 1/2 trial demonstrated improved results in patients with Ewing sarcomas.

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

Soon after experiencing headaches and other symptoms, I spoke up to my oncologist — and I’m glad I did.

From Shannen Doherty discussing in-vitro fertilization before breast cancer to "Chickadee" Cardwell's cancer experience to be featured on an upcoming TV series, here's what's happening in the oncology space this week.

An expert explained why chemotherapy-related amenorrhea in premenopausal women with breast cancer is “not just about having a period.”

As a comfort care companion for Moffitt Cancer Center, I sat vigil next to a dying patient with cancer with no family.

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Exploring holistic therapies can yield some interesting findings and benefits.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

Buddha once said, “To keep the body in good health is a duty... otherwise we shall not be able to keep our mind strong and clear.”

A patient in a phase 2 trial has received the first dose of a novel cancer vaccine plus Keytruda for solid skin cancer tumors.

The first patients has been dosed within the new CLARIFY trial for patients with prostate cancer awaiting prostatectomy.

The moment when I was told that my immune deficiency and rare cancer were linked.

A recent study found that breast cancer–specific survival in patients with invasive lobular carcinoma was inferior compared to patients with invasive ductal carcinoma.

The Food and Drug Administration stopped enrollment on a clinical trial evaluating LN-145 TIL for non-small cell lung cancer after a patient on the trial died.

From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.

The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).

I never thought I’d say it, but I miss my padded bras.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.

The pharmaceutical company submitted applications for the FDA to consider approval of Rybrevant plus lazertinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858 substitution mutations.

Lessons happen when you least expect it.

Dr. Stephanie Berg of Dana-Farber Cancer Institute and Harvard Medical School discusses the need to be mindful of quality of life when treating prostate cancer.

Managing a cancer support group isn't easy.

Experts look back on the year in the news regarding bispecific antibodies for the treatment of B-cell lymphomas including CLL and SLL.

Research focuses on the importance of quality of life and nutritional needs for patients with breast cancer.

Cancer. Such an expansive topic.

Diet and exercise can benefit patients with cancer through side effect management and improved outcomes. CURE provides an overview of the most-read diet and exercise stories of 2023.

The RELATIVITY-123 trial evaluating Opdualag in metastatic microsatellite stable colorectal cancer ended prematurely, according to the drug’s manufacturer.